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Data from phase 3 studies (NCT00224107, NCT00224120) of silodosin for treatment of BPH symp-
toms were analyzed to examine the relationship between treatment efficacy and occurrence of
abnormal ejaculation. Men aged X50 years with International Prostate Symptom Scores (IPSS) X13
and peak urinary flow rates (Qmax) of 4–15mls
 1 received placebo or silodosin 8mg once daily for
12 weeks. Silodosin-treated patients were stratified by absence or presence of ‘retrograde
ejaculation’ (RE). Groups were compared using analysis of covariance (for change from baseline)
and responder analyses. Of the 466 patients receiving silodosin, 131 (28%) reported RE and
335 (72%) did not; 4 of the 457 patients receiving placebo (0.9%) reported RE. Most RE events
in silodosin-treated patients (110/134; 82%) were reported as ‘orgasm with absence of seminal
emission.’ Silodosin-treated patients with (þ) and without ( ) RE showed significant improve-
ment in IPSS, Qmax and quality of life versus placebo (Po0.02). REþ patients versus RE  patients
experienced numerically greater improvement, but differences were not statistically significant
(P40.05). For REþ patients, the odds of achieving improvement of X3 points in IPSS and
X3mls
 1 in Qmax by study end were 1.75 times those for RE  patients (P¼0.0127). Absence of
seminal emission may predict superior treatment efficacy of silodosin in individual patients.
Prostate Cancer and Prostatic Diseases (2011) 14, 143–148; doi:10.1038/pcan.2010.46; published online 7 December 2010
Keywords: BPH; LUTS; a-blocker; retrograde ejaculation; IPSS score
Introduction
Treatment with a-blockers has been shown to relieve
BPH-related symptoms and improve urinary flow.
1,2
a-Blockers are believed to act by inducing smooth muscle
relaxation in the bladder neck, prostate and prostatic
capsule through the blockade of a1-adrenergic receptors.
A vast majority of a1-receptors in these tissues are
thought to belong to the a1a-receptor subtype.
1
The efficacy of providing symptom relief in patients
with BPH-associated lower urinary tract symptoms
(LUTS) is thought to be similar for all a-blockers,
regardless of their selectivity for a1-receptor subtypes,
including a1a-, a1b- and a1d-receptors.
3 However, a-
blockers differ in their safety and tolerability profiles,
4
particularly in their propensity to cause abnormal
ejaculation.
5 In controlled clinical trials, the percentage
of patients treated with the moderately a1a-selective a-
blocker tamsulosin who reported abnormal ejaculation
varied between 4 and 26%, depending on dose and study
duration.
6,7 In a long-term open-label extension study,
30% of patients treated with tamsulosin reported
abnormal ejaculation.
8 In contrast, incidences of abnor-
mal ejaculation related to the use of non-selective
a-blockers, such as doxazosin, terazosin or alfuzosin,
generally were lower than 1.5%.
3
The Medical Dictionary for Regulatory Activities (MedDRA),
the source for standard terminology for adverse events
recorded in clinical trials, uses ‘retrograde ejaculation’
(RE) as an umbrella term to describe a broad spectrum of
patient-reported events of abnormal ejaculation, includ-
ing absence of seminal emission, reduced ejaculate
volume and reduced ejaculation force. This terminology
reflects the formerly common belief that abnormal
ejaculation was mechanistically the result of RE. It was
assumed that pronounced relaxation of the bladder neck
muscle caused by blockade of a1a-receptors in this area
would lead to backflow of seminal fluid from the
prostatic urethra into the bladder. In contrast, contraction
of the bladder neck during orgasm and rhythmic
contraction of the bulbospongiosus muscle facilitate
propulsive ejaculation in the normal antegrade manner.
A recent placebo-controlled study that examined the
effects of tamsulosin and the non-selective a-blocker
alfuzosin on ejaculatory function in healthy volunteers
found that tamsulosin 0.8mg per day caused markedly
reduced ejaculate volume in 90% of patients and
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www.nature.com/pcananejaculation in 35% of patients. However, analysis of
post-climactic urine samples showed no increase
in sperm counts, suggesting that RE did not occur.
9
a1a-Receptors are abundant not only in the bladder neck
but also in the vas deferens and seminal vesicle. Recently,
it has been postulated that a1a-selective a-blockers cause
reduced or absent seminal emission by inhibiting smooth
muscle contraction in these genital tissues.
10
Silodosin is a newly approved a-blocker with unique
receptor subtype and tissue selectivity.
11–13 Compared
with tamsulosin, which has in vitro selectivities of 9.55
for human a1a versus a1b and B2.5 for a1a versus a1d,
silodosin is 162 times more selective for a1a than for a1b,
and is B55 times more selective for a1a than for a1d.
14 In
two 12-week randomized, placebo-controlled, multicen-
ter US studies, silodosin significantly improved BPH-
related LUTS and peak urinary flow rate (Qmax).
15
Results were consistent with the findings of clini-
cal studies of silodosin in Japanese patients.
12,16,17
Japanese and US phase 3 studies of silodosin reported
high incidences of abnormal ejaculation. Overall, 28% of
silodosin-treated patients in the two US studies reported
abnormal ejaculation (classified as RE), as did 22.3%
of silodosin-treated patients in the Japanese study.
16
A recent study in healthy volunteers suggests that
silodosin, similar to tamsulosin, induces the absence of
seminal emission rather than true RE.
18
If we assume that the efficacy of silodosin and its
propensity to cause abnormal ejaculation are both
attributable to the selective blockade of a1a-receptors, it
is reasonable to hypothesize that treated patients who
experience abnormal ejaculation may achieve greater
symptom relief than those with no ejaculatory distur-
bances. In this post hoc analysis of data from two placebo-
controlled US phase 3 trials of silodosin, we examined
the relationship between clinical efficacy and the absence
or presence of RE.
Materials and methods
Patients and treatment
This is a post hoc analysis of combined data from
two double-blind, placebo-controlled phase 3 studies
(SI04009 and SI04010) (ClinicalTrials.gov identifiers
NCT00224107 and NCT00224120) of silodosin in patients
with BPH-related LUTS.
15 Studies received Institutional
Review Board (IRB) approval. Eligibility criteria and
patient demographics have been described.
15 In brief,
patients were men aged X50 years with International
Prostate Symptom Score (IPSS) X13, with Qmax between
4 and 15mls
 1, voided volume X125ml, and post-void
residual urine volume o250ml. Patients (N¼923)
received 12 weeks of once-daily treatment with silodosin
8mg or placebo. The primary efficacy end point was
change from baseline in IPSS. IPSS and quality of life
questionnaires were completed at weeks 0, 0.5 (day
3 or 4), 1, 2, 4 and 12; Qmax was assessed at week 0, at
2–6h after the first dose, and at weeks 1, 2, 4 and 12.
Adverse events, reported spontaneously by the patient
or observed by the investigator, were recorded and
coded using the terminology of the MedDRA. All adverse
events were elicited from patients using an open-ended
question, such as ‘Since your last visit, have you noticed
any changes to your health?’ The MedDRA term ‘RE’ was
applied to ejaculatory dysfunction events described
in the case report forms as ‘orgasm, no semen,’ ‘orgasm,
semen quantity reduced,’ ‘orgasm, semen force reduced’
or ‘RE’ (verbatim). Worsening RE conditions were
recorded separately.
Assessments and statistical analyses
In this post hoc analysis, baseline characteristics and
efficacy data were stratified by ejaculation status among
patients treated with silodosin (that is, absence (RE )o r
presence (REþ) of RE). Pair-wise comparisons of
treatment effects were conducted for patients receiving
placebo versus each RE-stratified silodosin treatment
group and for the silodosin REþ versus the silodosin
RE  group.
To evaluate the relationship between ejaculation status
and silodosin efficacy, two responder analyses were
performed. For the first analysis, a patient was consid-
ered a responder if he experienced a 30% improvement
in both IPSS score and Qmax from baseline to the last
assessment. For the second analysis, a patient was
considered a responder if he experienced improvement
in Qmax of X3mls
 1 and in IPSS total score of X3
points.
For all comparisons, a significance level of 5% was
applied, with no adjustments for multiple comparisons.
Baseline characteristics were compared using analysis
of variance for continuous variables and a logistic
model for categorical variables with two levels. Pair-
wise comparison of efficacy parameters was performed
by analysis of covariance with baseline as covariate.
Responder analysis was performed using a logistic
regression model with no covariate. All P-values and
95% confidence intervals for odds ratios were derived
from the logistic model for assessment of group
equivalency; if the odds ratio of 1 was contained by the
95% confidence interval, responses in the compared
groups were considered not statistically different.
Results
Of 457 patients in the placebo group, only four (0.9%)
reported RE. Of 466 patients in the silodosin groups, 131
(28%) reported RE (silodosin REþ group), whereas 335
(72%) did not (silodosin RE  group); most RE events
(110 of 134; 82%) were reported as orgasm with no
seminal emission (Table 1). Reports of RE and treatment
discontinuation as a result of RE were age dependent.
The mean age of patients in the silodosin REþ group
was significantly lower than that of patients in the
silodosin RE  group (Po0.0001; Table 2). Of 150 patients
younger than 60 years who were treated with silodosin,
69 (46.0%) reported RE and 7 (4.7%) discontinued
because of RE. Of 191 patients aged 60–70 years, 48
(25.1%) reported RE and 6 (3.1%) discontinued, and of
125 patients older than 70 years, 14 (11.2%) reported RE
and none discontinued. Except for age, patients receiving
silodosin who reported RE and those who did not
receive silodosin had similar baseline characteristics
(Table 2).
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lation status, patients receiving silodosin versus placebo
experienced significant improvement in IPSS, including
total score and irritative and obstructive subscores
(Po0.0001), in Qmax (Po0.02) and in quality of life
(Po0.0001). Clinical improvements assessed by these
efficacy parameters were numerically greater in patients
with RE than in those without RE, but differences
between the silodosin REþ and RE  groups were not
statistically significant (Table 2, Figure 1).
To further analyze the relationship between ejacula-
tion status and efficacy, two responder analyses were
performed (see Materials and methods). The first
analysis found that, of the patients who received placebo,
9.2% achieved an improvement of at least 30% in both
IPSS and Qmax. In comparison, 20.9% of patients in the
silodosin RE  group and 27.5% in the silodosin REþ
group achieved at least 30% improvement in both IPSS
and Qmax (Figure 2). The second responder analysis
found that total IPSS improved by at least 3 points and
Qmax by at least 3mls
 1 (3 units of improvement) in
12.9% of patients receiving placebo compared with 23.0%
in the silodosin RE  group and 34.4% in the silodosin
REþ group (Figure 2).
The odds ratios versus placebo of achieving 30%
improvement were 2.61 for patients in the silodosin RE 
group (Po0.0001) and 3.74 for patients in the silodosin
REþ group (Po0.0001). The odds of 30% improvement
for patients in the silodosin REþ group were 1.43 times
those for patients in the silodosin RE  group (P¼0.1285)
(Table 3). The odds ratios versus placebo of achieving
improvement of 3 units were 2.01 (Po0.001) for patients
in the silodosin RE  group and 3.53 (Po0.0001) for
patients in the silodosin REþ group. The odds of
achieving improvement of 3 units for patients in the
silodosin REþ group were 1.75 times those for patients
in the silodosin RE  group, for a statistically significant
difference (P¼0.0127) (Table 3).
Discussion
This post hoc analysis of combined data from two US
phase 3 studies of silodosin revealed no major differences
in baseline parameters between patients who experienced
RE during 12 weeks of silodosin treatment and those
who did not, with the notable exception of age, which was
significantly different between the two groups. Thus, age
may have predictive value for the occurrence of silodosin-
related abnormal ejaculation. However, the observation
that patients who reported abnormal ejaculation were
younger than those who did not probably is merely a
reflection of the greater likelihood and frequency of sexual
activity in younger men.
Silodosin previously has been shown to promote signi-
ficant improvement in IPSS total score, with the mean
decrease from baseline to study end exceeding 6 points
and a mean drug-attributable effect (versus placebo) of
B3p o i n t s .
15 An improvement in IPSS of 2 points is the
minimum effect noticeable by patients as global symptom
improvement.
19 Thus, treatment with silodosin resulted in
overall symptom improvement that was three times the
minimum noticeable effect, and the drug-attributable
effect itself was greater than the minimum noticeable
effect. Silodosin compared with placebo promoted
statistically significant improvement in quality of life.
Previously published data from the combined phase 3
studies showed that over the course of the study, the
percentage of patients who were delighted, pleased or
mostly satisfied with their health-related quality of life
increased from 6.9% to 32.0% in the silodosin group and
from 7.2% to 22.5% in the placebo group.
15
When changes in IPSS and Qmax were compared,
silodosin-treated patients with RE had numerically
greater improvement than those without RE, but the
differences were not statistically significant. Responder
analyses were done to determine (1) the proportions
of patients with a minimum improvement of 30% in
both IPSS and Qmax and (2) the proportions of patients
with improvement of at least 3 units in both IPSS and
Qmax. Results showed that the proportions of patients
who achieved these levels of improvement were greater
among those with RE than among those without RE.
Furthermore, odds ratios indicated that patients with RE
were significantly more likely than those without RE
Table 2 Effect of retrograde ejaculation status on baseline chara-
cteristics and changes from baseline in efficacy parameters
Variable, mean (s.d.) Placebo Silodosin RE  Silodosin RE+
(n¼457) (n¼335) (n¼131)
Baseline data
Age, years 64.7 (8.06) 66.1 (8.20) 60.8 (6.28)
a,b
BMI, kgm
 2 28.5 (4.30) 28.6 (4.65) 28.6 (4.51)
IPSS total score 21.3 (4.91) 21.0 (5.14) 22.2 (5.01)
IPSS irritative subscore 9.3 (2.51) 9.3 (2.59) 9.4 (2.60)
IPSS obstructive
subscore
12.0 (3.53) 11.7 (3.59) 12.8 (3.38)
Qmax, mls
 1 8.9 (2.76) 8.6 (2.61) 8.9 (2.41)
QoL 4.0 (1.07) 3.9 (1.05) 4.1 (1.05)
Changes from baseline to week 12 (LOCF)
IPSS total score  3.5 (5.84)  6.1 (6.36)
c  7.2 (7.23)
c
IPSS irritative subscore  1.4 (2.66)  2.2 (2.84)
c  2.6 (3.15)
c
IPSS obstructive
subscore
 2.1 (3.76)  3.8 (4.19)
c  4.6 (4.59)
c
Qmax, mls
 1 1.5 (4.36) 2.4 (4.29)
d 3.1 (4.76)
d
QoL  0.4 (1.14)  0.8 (1.29)
c  1.0 (1.35)
c
Abbreviations: BMI, body mass index; IPSS, International Prostate Symptom
Score; LOCF, last observation carried forward; Qmax, peak urinary flow rate;
QoL, quality of life; RE, retrograde ejaculation.
aPo0.0001 versus silodosin RE .
bPo0.001 versus placebo.
cPo0.0001 versus placebo.
dPo0.02 versus placebo.
Table 1 Incidence of retrograde ejaculation in two silodosin phase
3 studies by MedDRA subterms
MedDRA preferred subterm No. (percentage) of patients,
No. of events
Placebo
(n¼457)
Silodosin
(n¼466)
Orgasm, no semen 3 (0.7), 3 107 (23.0), 108
Orgasm, no semen (worsening) 0 2 (0.4), 2
Orgasm, semen quantity reduced 1 (0.2), 1 15 (3.2), 15
Orgasm, semen quantity reduced
(worsening)
0 6 (1.3), 6
Orgasm, semen force reduced
(worsening)
0 1 (0.2), 1
Retrograde ejaculation (verbatim) 0 2 (0.4), 2
Abbreviation: MedDRA, Medical Dictionary for Regulatory Activities.
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at least 3 points and Qmax improvement by at least
3mls
 1). Compared with the placebo group, both
silodosin groups showed significantly greater improve-
ment in IPSS and Qmax in the two responder analyses.
Silodosin has been shown to be very effective in the
treatment of patients with BPH-associated LUTS and
to cause abnormal ejaculation in almost one-third of
treated patients.
15 It has been suggested that a1a-selective
a-blockers, such as silodosin, can cause absence of
seminal emission by inhibiting smooth muscle contrac-
tion in genital tissues. If the results of our post hoc
analysis are substantiated by future studies, the absence
of seminal emission for individual patients with BPH-
related symptoms could be a sensitive indicator of
a positive response to treatment with an a1a-selective
a-blocker. Thus, ejaculatory status could help to identify
men who are particularly responsive to such a therapy.
However, the biological basis for lesser or greater
responsiveness to therapy with a1a-selective a-blockers
remains unclear.
This post hoc analysis has important limitations.
A variety of adverse events spontaneously reported by
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Figure 1 Mean changes from baseline in total IPSS (a), IPSS irritative subscore (b), IPSS obstructive subscore (c), Qmax (d) and QoL (e)b y
ejaculation status. Error bars indicate 95% confidence intervals. Abbreviations: BL, baseline; IPSS, International Prostate Symptom Score;
LOCF, last observation carried forward; Qmax, peak urinary flow rate; QoL, quality of life; RE, retrograde ejaculation.
Figure 2 Patient response to silodosin treatment by ejaculation
status. A patient was considered a responder if he experienced a
30% improvement in IPSS and Qmax or both an improvement in
IPSS by at least 3 points and an improvement in Qmax by at least
3mls
 1. Analyses were based on changes from baseline to week 12
(LOCF). IPSS, International Prostate Symptom Score; LOCF, last
observation carried forward; Qmax, peak urinary flow rate; RE,
retrograde ejaculation.
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‘RE.’ Most events of RE appeared to be events of no or
reduced seminal emission during orgasm. Several con-
ditions had to be met for an event of RE to be reported:
the patient had to be sexually active, had to remember
the event until the next clinical visit and had to consider
the event worth reporting. The observations reported in
this study could be explained in part by the theoretical
possibility that men with erectile dysfunction were less
likely to respond to a-blockers than were other patients;
however, no evidence to support this assumption is
available from the published literature. Furthermore,
the number of patients who reported RE in this study
was too small for the performed analyses to have
sufficient statistical power. Consequently, the reported
findings are preliminary and are not intended to
establish a causal relationship between the efficacy of
silodosin and the occurrence of RE. To substantiate a link
between clinical efficacy and ejaculatory status in
men treated with silodosin, prospective studies suffi-
ciently powered to demonstrate significant differences
in clinical outcomes depending on the presence or
absence of seminal emission are needed. In addition,
such studies should require detailed questionnaires
that rigorously address sexual activity and ejaculatory
function.
Results of this post hoc analysis suggest a possible
relationship between silodosin efficacy and the occur-
rence of abnormal ejaculation as a result of treatment.
This analysis showed that silodosin-treated patients who
were experiencing abnormal ejaculation were signifi-
cantly more likely to achieve a minimum improvement
of 3 units in both IPSS and Qmax than were those
with normal ejaculatory function. This observation
suggests that reduced or absent seminal emission in a
patient treated with silodosin may predict greater
treatment efficacy. The biological basis for differences
in treatment response among individual patients remains
to be elucidated.
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